10 Oct 2026

CRC Research Update — October 10, 2026

Creator: The CRC Digest
Published: 2026-10-10T11:29:35Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

SCREENING
NordICC trial on colonoscopy screening published
TREATMENT
French trial tests reintroducing chemotherapy after liver metastasis resection
The IRIMAD phase III trial is randomizing patients who responded well to preoperative FOLFIRI and underwent curative resection of metachronous colorectal liver metastases to postoperative FOLFIRI reintroduction in the experimental arm. (Dig Liver Dis)
RESEARCH
Non-metastatic lymph node subtypes may refine risk stratification
Researchers developed a histopathological classification system for non-metastatic lymph nodes, stimulated, unstimulated, and depleted subtypes, and an interpretable machine-learning model for patient-level risk stratification in colorectal cancer. (Mod Pathol)
RESEARCH
Chinese herbal formulation may shift pMMR tumors toward dMMR-like phenotype
Preclinical research using mouse models found that Xian-Lian-Jie-Du decoction (XLJDD) may modulate proficient mismatch repair (pMMR) colorectal tumors toward a dMMR-like phenotype, potentially enhancing responsiveness to anti-PD-1 therapy. (Phytomedicine)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Polyp detection in under-45 diagnostic colonoscopy
A retrospective study of 727 patients aged 18-44 undergoing non-screening colonoscopy evaluated histologically confirmed colorectal polyps and examined predictors including age, sex, and BMI. (Cureus)
Prediction model for bowel prep quality in patients ≤50
Researchers developed and internally validated a prediction model for suboptimal bowel preparation in 2,283 individuals aged ≤50 years undergoing colonoscopy, using the Boston Bowel Preparation Scale. (Front Med)

🧬 Biomarker Spotlight

Research by genetic subtype. KRAS, BRAF, MSI-H, HER2, and more

KRAS mutations in 63.54% of metastatic CRC patients
A retrospective study of 96 patients with metastatic colorectal cancer found KRAS mutations in 63.54% of patients, predominantly in codon 12 (70.49%) and codon 13 (14.75%). (Arq Bras Cir Dig)

Today's research spans screening quality, adjuvant strategy trials, and biomarker-driven approaches to immunotherapy resistance.

Get CRC research intelligence delivered weekly, free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest